The company issued common stock in the SEC-registered at-the-market offering

Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Aligos Therapeutics, Inc. of its common stock for up to an aggregate amount of $75 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “ALGS.”

Aligos is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis. Aligos Therapeutics is headquartered in South San Francisco, California.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Beth LeBow and Elsie Cheang. Partner Michael Farber and associate Benjamin Helfgott provided tax advice. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. Associate Leon E. Salkin provided 1940 Act advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post